The Journal of
Clinical Psychiatry

Neurology Dementia

Letter to the Editor July 15, 2003

Olanzapine/Risperidone and Diabetes Risk

David W. Lee, PhD; Robert B. Fowler, BA

J Clin Psychiatry 2003;64(7):847-848

Article Abstract

Letter to the Editor

Olanzapine/Risperidone and Diabetes Risk.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue

Letter to the Editor

Why Ask Patients to Cut Into Quarters 10 mg THC Gummies From a Dispensary When 2.5 mg THC Is Available by Prescription?

June 5, 2024

The authors discuss a study by Sawicki et al of dementia patients for whom 2.5 mg of THC was recommended for neuropsychiatric symptoms.

Marina Goldman, Dimitri Markov

Letter to the Editor

THC Edible Gummies for Behavioral Symptoms of Dementia: Reply to Goldman and Markov

June 5, 2024

The authors reply to Goldman and Markov’s comments on their recent study of dispensary-obtained THC for dementia.

Erin K. Zahradnik, Cristian Hernandez

Letter to the Editor

Insights Into Poststroke Depression

August 31, 2023

The authors shed light on risk factors, purported mechanisms, diagnostic tips, and treatment options for poststroke depression.

Ahmed Naguy, Bibi Alamiri

Olanzapine/Risperidone and Diabetes Risk

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

ELSEWHERE:

FOLLOW US:

Olanzapine/Risperidone and Diabetes Risk

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

Related Articles

Why Ask Patients to Cut Into Quarters 10 mg THC Gummies From a Dispensary When 2.5 mg THC Is Available by Prescription?

THC Edible Gummies for Behavioral Symptoms of Dementia: Reply to Goldman and Markov

Insights Into Poststroke Depression

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles